Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)-Reference-Cited by-同舟云学术

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Published:2016-01-09 Issue:6 Volume:7 Page:6984-6993
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Lee Ji Yun¹,Qing Xu²,Xiumin Wei²,Yali Bai²,Chi Sangah³,Bak So Hyeon⁴,Lee Ho Yun⁵,Sun Jong-Mu¹,Lee Se-Hoon¹,Ahn Jin Seok¹,Cho Eun Kyung⁶,Kim Dong-Wan⁷,Kim Hye Ryun⁸,Min Young Joo⁹,Jung Sin-Ho³,Park Keunchil¹,Mao Mao²,Ahn Myung-Ju¹

Affiliation:

1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2. Translational Bioscience and Diagnostics, WuXi AppTec, Waigaoqiao Free Trade Zone, Shanghai, China

3. Department of Biostatistics and Bioinformatics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

4. Department of Radiology, Kangwon National University Hospital, Chuncheon, Korea

5. Department of Radiology, Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

6. Division of Hematology-Oncology, Department of Medicine, Gachon Medical School, Gil Medical Center, Inchon, Korea

7. Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

8. Division of Oncology, Department of Medicine, Yonsei University College of Medicine, Seoul, Korea

9. Department of Oncology, Asan Medical Center, University of Ulsan college of Medicine, Seoul, Korea

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulation of rare events in the liquid biopsy for early detection of lung mass lesions;Thoracic Cancer;2024-09-04

2. Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors;Future Oncology;2024-09-04

3. A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17);ESMO Open;2024-09

4. Application of liquid biopsy in lung cancer management;Indian Journal of Pathology and Microbiology;2024-07

5. Early acquired resistance to EGFR-TKIs in lung adenocarcinomas before radiographic advanced identified by CT radiomic delta model based on two central studies;Scientific Reports;2023-09-20